利用肝脂肪变的偶发影像学发现改善代谢功能障碍相关脂肪性肝病的诊断
本文综述了在因非肝脏疾病行影像检查时发现肝脂肪变后,如何依据推荐意见采用无创检查预测进展期肝纤维化,以识别更多代谢功能障碍相关脂肪性肝病(MASLD)患者,并指出MASLD新疗法已获批使该领域研究意义重大。
要点
- 因非肝脏原因行影像检查时发现肝脂肪变,可作为MASLD机会性筛查的切入点。
- MASLD患者中肝纤维化分期是死亡的最重要预测因素,早期识别进展期肝纤维化高危患者至关重要。
- 无创检查可预测进展期肝纤维化,推荐用于基层医疗以决定哪些患者最受益于专科诊疗。
核心结论
- 影像检查中偶发发现的肝脂肪变可为识别更多MASLD患者提供机会性筛查途径,结合无创检查预测纤维化分期有助于早期识别进展期肝纤维化高危患者。
研究设计与样本
- 本文为综述,回顾了影像发现肝脂肪变时的推荐意见及可用于帮助预测纤维化分期的无创检查。
临床应用与阅片要点
- 原文指出无创检查预测进展期肝纤维化并推荐用于基层医疗以确定最受益于专科诊疗的患者,但此类工具的采用并不广泛,且多项研究报告MASLD合并糖尿病患者中肝硬化存在认识不足。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of liver disease worldwide. In patients with MASLD, liver fibrosis stage is the most significant predictor of mortality; therefore, early identification of patients at the greatest risk of advanced fibrosis is essential. Noninvasive tests predict advanced fibrosis and are recommended for use in primary care settings to determine which patients would benefit most from specialty care. The adoption of these tools is not widespread, and several studies have reported underrecognition of cirrhosis in patients with MASLD and diabetes. The finding of hepatic steatosis on imaging performed for evaluation of nonliver conditions may present an avenue for opportunistic screening to identify more patients with MASLD. This article will review recommendations for when hepatic steatosis is found on imaging and noninvasive tests that can be used to help predict fibrosis staging. This is a significant area of research because a new treatment for MASLD has been approved, and other treatments may follow.
引用
- Schonfeld E, Kierans AS, Fox R, et al. Using Incidental Radiologic Findings of Hepatic Steatosis to Improve the Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease. J Am Coll Radiol. 2025. PMID: 40044315. doi:10.1016/j.jacr.2024.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。